The Utilization and Safety of Umeclidinium and Umeclidinium/Vilanterol in UK Primary Care: A Retrospective Cohort Study.

Gema RequenaDaniel Dedman Jennifer Kathleen Quint Rebecca Elisabeth GhoshRachael WilliamsJeanne M Pimenta

Published in: International journal of chronic obstructive pulmonary disease (2021)

Most new users of UMEC were receiving multiple-inhaler triple therapy. Off-label prescribing was uncommon for new users of UMEC and UMEC/VI. Incidence of cardiovascular and respiratory outcomes was as expected for these drug classes. This study provides evidence that UMEC and UMEC/VI are being prescribed appropriately and their safety profile remains unchanged.

Keyphrases

primary care
type diabetes
adverse drug
stem cells
drug induced
mesenchymal stem cells
weight loss
smoking cessation